Patents by Inventor Peipei WANG

Peipei WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10822327
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 3, 2020
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Patent number: 10686582
    Abstract: An apparatus and method is provided that compensates for the supply droops to minimize strobe shifts and to regain eye margin. The apparatus includes a droop detector to detect voltage droops at one or more trip (or threshold) levels and these detected voltage droops are translated to a shift in clock phase setting. For example, propagation delay of a delay locked loop (DLL) and/or clock edge selection from a phase interpolator (PI) is adjusted according to the detected voltage droop levels to maintain a trained relationship between the sampling clock strobe and data eye. A lookup table is used to determine a PI code or a DLL propagation delay code corresponding to a voltage droop level.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 16, 2020
    Assignee: Intel Corporation
    Inventors: Gerald Pasdast, Nasser A. Kurd, Peipei Wang, Yingyu Miao, Lakshmipriya Seshan, Ishaan S. Shah
  • Publication number: 20200142171
    Abstract: A structured illumination microscopic imaging system includes a structured illumination source. A beam shaping lens, an excitation optical filter and a dichroic mirror are provided on the emission light path of the structured illumination source in sequence. An objective lens and a sample are provided on the first optical path of the dichroic mirror in sequence. An emission optical filter, a tube lens, and a detector are provided on the second optical path of the dichroic mirror in sequence. The super-resolution microscopic images with a higher signal-to-noise ratio and higher contrast can be obtained under the premise of lowering the installation and processing precision requirements of the structured illumination microscopic imaging system. Compared to a structured light microscopic imaging system based on digital micromirror arrays or gratings, the system cost is reduced and the system stability is higher.
    Type: Application
    Filed: June 20, 2017
    Publication date: May 7, 2020
    Applicant: Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences
    Inventors: Daxi XIONG, Xibin YANG, Peipei WANG
  • Publication number: 20200140454
    Abstract: The present invention provides compounds of Formula (I) which can be used as ACC inhibitors and potently as therapeutic agents against diseases mediated by ACC.
    Type: Application
    Filed: July 17, 2018
    Publication date: May 7, 2020
    Applicant: NANJING RUIJIE PHARMATECH CO., LTD.
    Inventors: Junbo Zhang, Hong Liao, Peipei Wang, Peng Wang
  • Publication number: 20190375727
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 12, 2019
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Publication number: 20190041895
    Abstract: A processing device includes a package, a plurality of dies disposed on the package, where each die comprises a clock receiver, and a single common clock source to generate a common clock signal. The processing device also includes a clock distribution circuitry coupled to the single common clock source. The clock distribution circuitry distributes the common clock signal from the single common clock source to each of the plurality of dies individually. The clock distribution circuitry includes a first group of terminated transmission lines. The first group of terminated transmission lines includes a first terminated transmission line, a second terminated transmission line, and a first termination resistor coupled between the first terminated transmission line and the second terminated transmission line. The first terminated transmission line and the second terminated transmission line receive the common clock signal from the single common clock source.
    Type: Application
    Filed: April 12, 2018
    Publication date: February 7, 2019
    Inventors: Yingyu Miao, Gerald Pasdast, Peipei Wang, Mahesh Kumashikar
  • Publication number: 20180046205
    Abstract: A pressure reducing valve and a pressure reducing system are provided. The pressure reducing valve includes a main valve body in which a valve chamber is formed; the main valve body is provided with a valve outlet and a valve inlet communicating with the valve chamber; and at least two pressure reducing devices adapted between the valve inlet and the valve outlet to depressurize the fluid at the valve inlet and discharge to the valve outlet. The pressure reducing valve occupies a small space, low cost and low pressure leakage point. Each pressure reducing device shares a main valve body, independent of each other, do not interfere with each other, and can be flexible to switch or use at the same time. The pressure reducing system is provided with at least one regulating member, which comprising an adjustment medium outlet section which communicates with the valve chamber through the valve body and the valve seat.
    Type: Application
    Filed: August 9, 2017
    Publication date: February 15, 2018
    Applicant: Beijing Huashi United Energy Technology and Development Co., Ltd.
    Inventors: Lin Li, Lixin Guo, Na Wang, Zhenduo Li, Yang Lu, Peipei Wang
  • Patent number: 9662349
    Abstract: The present invention discloses a Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide having efficacy for regulating tumor microenvironment, whose active components are complexed by Lucid Ganoderma polysaccharide, Lycium barbarum polysaccharide and Polygonatum sibiricum polysaccharide, the mass proportion ratio of each component is Lucid Ganoderma polysaccharide 10-250, Lycium barbarum polysaccharide 1-50, Polygonatum sibiricum polysaccharide 2-10. The Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide is high in purity and activity, has an efficacy for regulating tumor microenvironment. The present invention also discloses the preparation method of aforesaid Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide, said method is simple, stable and efficient in the process, suitable for industrial production and economic.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: May 30, 2017
    Assignee: Infinitus (China) Company Ltd.
    Inventors: Minghua Hu, Fangli Ma, Peipei Wang, Ming Liang
  • Publication number: 20150366896
    Abstract: The present invention discloses a Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide having efficacy for regulating tumor microenvironment, whose active components are complexed by Lucid Ganoderma polysaccharide, Lycium barbarum polysaccharide and Polygonatum sibiricum polysaccharide, the mass proportion ratio of each component is Lucid Ganoderma polysaccharide 10-250, Lycium barbarum polysaccharide 1-50, Polygonatum sibiricum polysaccharide 2-10. The Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide is high in purity and activity, has an efficacy for regulating tumor microenvironment. The present invention also discloses the preparation method of aforesaid Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum complex polysaccharide, said method is simple, stable and efficient in the process, suitable for industrial production and economic.
    Type: Application
    Filed: February 6, 2015
    Publication date: December 24, 2015
    Applicant: Infinitus (China) Company Ltd.
    Inventors: Minghua HU, Fangli MA, Peipei WANG, Ming LIANG